• One-step TUNEL Cy3 Kit for CRC Apoptosis

  2026-09-03

  Discover how the One-step TUNEL Cy3 Apoptosis Detection Kit can clarify DNA fragmentation in colorectal cancer models. This guide connects AKT1-directed pharmacology, translational tissue analysis, and rigorous apoptosis assay design.

• Nitroaromatic Nannocystin Targets AKT1 in CRC

  2026-09-03

  The reference study identifies a synthetic nitroaromatic nannocystin that suppresses colorectal cancer models and shows in vivo activity in a patient-derived xenograft. Its integrated synthesis, organoid, animal, transcriptomic, docking, and cellular thermal shift analyses support AKT1 as a contributing molecular target while defining important limits for translation.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-02

  The reference study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its experiments showed tumor-localized protein expression, restoration of p21-dependent cell-cycle control, and suppression of orthotopic tumor growth, while also defining important limitations for translation beyond preclinical models.

• Making Epigenetic Plasticity Visible in HNSCC

  2026-09-02

  Metastatic head and neck squamous cell carcinoma is shaped by changing cellular identities, not fixed tumor subtypes. This thought-leadership article connects recent multi-omic findings on WDR54-driven plasticity with spatial protein and RNA imaging, showing how Cy5-based tyramide amplification can help translational teams test lineage transitions, detect scarce biomarkers, and design more decision-ready validation studies.

• Chenodeoxycholic Acid: From FXR to Renal Protection

  2026-09-01

  Chenodeoxycholic Acid is more than a bile acid metabolism tool. By activating FXR, CDCA enables mechanism-led research spanning cholesterol homeostasis, nuclear receptor signaling, and the FXR–KLF11–JAK2/STAT3 axis in contrast-induced acute kidney injury.

• EZ Cap™ OVA mRNA for Better Immune Models

  2026-09-01

  A translational framework for using Cap 1-capped Ovalbumin mRNA to separate antigen biology from delivery-driven inflammation, improve experimental consistency, and inform next-generation vaccine development research.

• Fluorescein TSA Fluorescence System Kit for Astrocytes

  2026-08-31

  Translate astrocyte atlas discoveries into spatially resolved protein and RNA validation with localized tyramide signal amplification. This workflow is especially useful when conventional fluorescence cannot resolve low-abundance markers across developmental stages, brain regions, or species.

• 10058-F4 C-Myc-Max Dimerization Inhibitor

  2026-08-31

  10058-F4 is a small-molecule c-Myc-Max dimerization inhibitor that disrupts c-Myc/MAX-dependent transcription and supports mechanistic studies of apoptosis, acute myeloid leukemia, and prostate cancer models. Catalog data describe research-use formulations, while a 2024 human pluripotent stem-cell preprint links low-dose c-Myc:MAX inhibition to reduced TERT transcription and increased H3K27me3 at the TERT promoter.

• Clozapine in Translational Schizophrenia Research

  2026-08-30

  A thought-leadership framework for using Clozapine to connect receptor pharmacology, ERK1/2 signaling activation, prefrontal-cortex biology, circuit modulation, and safety-oriented translational design in schizophrenia research.

• Cheminformatics Design of Optimized Small-Molecule Libraries

  2026-08-29

  Moret et al. present a data-driven framework for evaluating and designing focused small-molecule libraries using target coverage, binding selectivity, cellular phenotypes, chemical structure, clinical-development status, and user priorities. The approach generated kinase and mechanism-of-action collections with improved coverage and reduced redundancy, providing a practical basis for more interpretable chemical-genetic experiments.

• ABT-263 (Navitoclax) in Apoptosis Assays

  2026-08-28

  ABT-263 (Navitoclax) converts Bcl-2-family dependence into a measurable mitochondrial apoptosis phenotype, making it useful for cancer-cell sensitivity profiling, combination studies, and resistance analysis. This guide pairs practical apoptosis assay design with a motility-aware framework inspired by recent melanoma research.

• 20-HETE, TRPV1, and Itch in Chronic Dermatitis

  2026-08-28

  This study identifies a peripheral mechanism for allokinesis, in which normally painful capsaicin becomes itch-provoking in chronic dermatitis. By combining sensory-neuron manipulation, electrophysiology, metabolomics, and pharmacological inhibition, the authors connect elevated 20-HETE to TRPV1 activation in sensitized MrgprA3+ neurons.

• Triterpene Prodrug for Targeted OSCC Chemotherapy

  2026-08-27

  This 2024 ACS Applied Materials & Interfaces study developed a carrier-free, self-assembled prodrug from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. Its central innovation is a thioketal-linked ROS-responsive design in which glycyrrhetinic acid helps amplify oxidative stress, promoting further drug release and synergistic tumor-cell apoptosis.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-08-27

  Neuromedin S (rat), SKU B5466, provides a defined peptide input for controlled neuromedin U receptor signaling and GPCR/G protein signaling experiments. It is suitable for research assay development and rat-focused pathway studies, but should not be used to infer potency, therapeutic activity, diagnostic performance, or cross-species validity when directly matched paper evidence is unavailable.

• Ribociclib, Acid Reduction, and pH-Mediated Absorption

  2026-08-26

  Desai and colleagues combined an Analytical Quality by Design framework with a biorelevant micro-dissolution model to examine whether physiological pH shifts could alter ribociclib succinate solubility in the presence of acid-reducing therapy. Although solubility decreased after gastric and intestinal pH transitions, the authors concluded that the changes were unlikely to produce a clinically meaningful absorption interaction, while emphasizing the value of this workflow for early formulation and drug-interaction risk assessment.

557 records 6/38 page Previous Next First page 上5页 678910 下5页 Last page